MiMedx Group (NASDAQ:MDXG – Get Free Report) announced its earnings results on Wednesday. The company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.07, Zacks reports. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%.
MiMedx Group Stock Performance
MiMedx Group stock traded up $0.05 during mid-day trading on Wednesday, reaching $8.01. The company’s stock had a trading volume of 562,154 shares, compared to its average volume of 563,991. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of 14.56 and a beta of 1.94. The business has a 50 day moving average price of $8.78 and a 200-day moving average price of $7.68. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. MiMedx Group has a twelve month low of $5.47 and a twelve month high of $10.14.
Wall Street Analysts Forecast Growth
Separately, StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $12.00.
About MiMedx Group
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.
Recommended Stories
- Five stocks we like better than MiMedx Group
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Buffett’s on the Sidelines – Should You Follow?
- Best Stocks Under $5.00
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- Most Volatile Stocks, What Investors Need to Know
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.